2. Search Result
Search Result
Pathways Recommended: Antibody-drug Conjugate/ADC Related
Results for "

peptide-drug conjugate

" in MedChemExpress (MCE) Product Catalog:

9

Inhibitors & Agonists

9

Peptides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P10895
    HR97 TFA

    		Biochemical Assay Reagents Others
    HR97 TFA is a cell-penetrating peptide that can be combined with engineered melanin to prepare eye drops HR97-SunitiGel. The peptide-drug conjugate in HR97-SunitiGel can provide sustained ocular drug delivery .
    HR97 TFA
  • HY-P4073
    ANG1005

    GRN1005; Paclitaxel trevatide

    		 Peptide-Drug Conjugates (PDCs) LDLR Cancer
    ANG1005 (Paclitaxel trevatide) is a brain-penetrating peptide-drug conjugate. ANG1005, a taxane derivative, consists of three paclitaxel (HY-B0015) molecules covalently linked to Angiopep-2, designed to cross the blood-brain and blood-cerebrospinal barriers and to penetrate malignant cells via low density lipoprotein receptor-related protein (LRP1) transport system .
    ANG1005
  • HY-P10947
    MACTIDE-V

    		Epigenetic Reader Domain YAP Cancer
    MACTIDE-V is an orally active and selective peptide-drug conjugate targeting CD206. MACTIDE-V delivers Verteporfin (HY-B0146) to CD206 + tumor-associated macrophages (TAM) to inhibit the YAP/TAZ signaling pathway, prompting YAP exclusion from the nucleus, inducing TAM polarization toward an anti-tumoral phenotype with enhanced phagocytosis and antigen presentation, and boosting T cell infiltration and NK cell activity. MACTIDE-V suppresses primary tumor growth and lung metastasis in triple-negative breast cancer (TNBC) mouse models .
    MACTIDE-V
  • HY-P10757
    DTX-P7

    		Peptide-Drug Conjugates (PDCs) Apoptosis HSP Eukaryotic Initiation Factor (eIF) PERK Cancer
    DTX-P7 is a peptide-drug conjugate. DTX-P7, composed of Docetaxel (DTX, HY-B0011) and a heptapeptide (P7), induces unfolded protein response and subsequent apoptosis by degrading Hsp90 .
    DTX-P7
  • HY-P10760
    PhAc-ALGP-Dox

    		Peptide-Drug Conjugates (PDCs) Cancer
    PhAc-ALGP-Dox, a peptide-drug conjugate, is a novel anticancer prodrug, with IC50 values ranged from 311 nM to 34.25 μM for TNBC (E0771), normal murine epithelium (HC-11), human TNBC (MDA-MB-231 and MDA-MB-468), human CrC (LS 174T), normal human epithelium (HME-1) cells .
    PhAc-ALGP-Dox
  • HY-P10762
    CBP-1008

    LDC 10B

    		 Peptide-Drug Conjugates (PDCs) Folate Receptor (FR) TRP Channel Cancer
    CBP-1008 is a dual-ligand peptide-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. CBP-1008 binds to FRα with high affinity and TRPV6 with low affinity. CBP-1008 has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma) .
    CBP-1008
  • HY-P10741
    DOTA-EB-TATE

    		Radionuclide-Drug Conjugates (RDCs) Peptide-Drug Conjugates (PDCs) Somatostatin Receptor Cancer
    DOTA-EB-TATE is composed of SST peptide derivative, DOTA-octreotate conjugated a common to an Evans blue analog (EB). DOTA-EB-TATE is a peptide drug conjugate (PDC) improves the pharmacokinetics of SSTR2 analogs and reduces PRRT toxicity. DOTA-EB-TATE can also be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
    DOTA-EB-TATE
  • HY-P10742
    CBX-12

    		Peptide-Drug Conjugates (PDCs) Topoisomerase Cancer
    CBX-12 is a PDC (peptide drug conjugate) that targets tumors in an antigen-independent manner and exhibits antitumor activity. CBX-12 consists of a pH-sensitive peptide (pHLIP), a self-immolating linker, and a topoisomerase 1 (TOP1) inhibitor Exatecan (HY-13631) .
    CBX-12
  • HY-P10740
    CBP-1018

    		Peptide-Drug Conjugates (PDCs) Antifolate Cancer
    CBP-1018 is a PDC (peptide drug conjugate) consisting of a dual targeting FRα/prostate-specific membrane antigen (PSMA) ligand (blue part) coupled to Monomethyl auristatin E (HY-15162) (red part) via a linker (HY-78738) (black part). CBP-1018 is expected to be used in breast cancer research .
    CBP-1018

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: